The present work reports updated oncological results and patients-reported outcomes at 5 years of phase II trial "Short-term high precision RT for early prostate cancer with SIB to the dominant intraprostatic lesion (DIL) for patients with early-stage PCa".
Data from patients enrolled within AIRC IG-13218 (NCT01913717) trial were analyzed. Clinical and GU/GI toxicity assessment and PSA measurements were performed every 3 months for at least 2 years after RT end. QoL of enrolled patients was assessed by IPSS, EORTC QLQ-C30, EORTC QLQ-PR25, and IIEF-5. Patients' score changes were calculated at the end of RT and at 1, 12, and 60 months after RT.
A total of 65 patients were included. At a median follow-up of 5 years, OS resulted 86%. Biochemical and clinical progression-free survival at 5 years were 95%. The median PSA at baseline was 6.07 ng/ml, while at last follow-up resulted 0.25 ng/ml. IPSS showed a statistically significant variation in urinary function from baseline (p = 0.002), with the most relevant deterioration 1 month after RT, with a recovery toward baseline at 12 months (p ≤ 0.0001). A numerical improvement in QoL according to the EORTC QLQ-C30 has been reported although not statistically significant. No change in sexual activity was recorded after RT.
The study confirms that extreme hypofractionation with a DIL boost is safe and effective, with no severe effects on the QoL. The increasing dose to the DIL does not worsen the RT toxicity, thus opening the possibility of an even more escalated treatment.
World journal of urology. 2024 Mar 16*** epublish ***
Giulia Marvaso, Giulia Corrao, Ilaria Repetti, Chiara Lorubbio, Federica Bellerba, Mattia Zaffaroni, Maria Giulia Vincini, Dario Zerini, Sarah Alessi, Stefano Luzzago, Francesco Alessandro Mistretta, Cristiana Fodor, Raffaella Cambria, Federica Cattani, Francesco Ceci, Gennaro Musi, Ottavio De Cobelli, Thomas Zilli, Sara Gandini, Roberto Orecchia, Giuseppe Petralia, Barbara Alicja Jereczek-Fossa
Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy., Department of Experimental Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy., Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy. ., Division of Radiology, IEO European Institute of Oncology IRCCS, Milan, Italy., Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Medical Physics Unit, IEO European Institute of Oncology IRCCS, Milan, Italy., Department of Radiation Oncology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland., Scientific Directorate, IEO European Institute of Oncology IRCCS, Milan, Italy.